| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 48 |
| 1 | METHOTREXATE | 43 |
| 2 | CYTARABINE | 34 |
| 3 | VINCRISTINE SULFATE | 33 |
| 4 | MERCAPTOPURINE | 26 |
| 5 | CYCLOPHOSPHAMIDE | 23 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 23 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 23 |
| 8 | ETOPOSIDE | 18 |
| 9 | PREDNISONE | 18 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR | 2 | 0.0025 |
| 1 | CARBAMIDE PEROXIDE | 1 | 0.0023 |
| 2 | THIOGUANINE | 4 | 0.0019 |
| 3 | MERCAPTOPURINE | 26 | 0.0015 |
| 4 | PURIXAN | 1 | 0.0013 |
| 5 | ALGLUCOSIDASE ALFA | 3 | 0.0012 |
| 6 | VINCRISTINE SULFATE | 33 | 0.0011 |
| 7 | BREXUCABTAGENE AUTOLEUCEL | 2 | 0.0009 |
| 8 | PEGASPARGASE | 10 | 0.0008 |
| 9 | IDECABTAGENE VICLEUCEL | 1 | 0.0008 |
| # | Drug class | Count |
|---|---|---|
| 0 | Folate Analog Metabolic Inhibitor [EPC] | 46 |
| 1 | Corticosteroid [EPC] | 39 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 36 |
| 3 | Alkylating Drug [EPC] | 24 |
| 4 | Topoisomerase Inhibitor [EPC] | 18 |
| 5 | Platinum-based Drug [EPC] | 16 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 11 |
| 7 | Asparagine-specific Enzyme [EPC] | 10 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 10 |
| 9 | Proton Pump Inhibitor [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 3 | 0.0009 |
| 1 | Dihydrofolate Reductase Inhibitor Antimalarial [EPC] | 1 | 0.0008 |
| 2 | Asparagine-specific Enzyme [EPC] | 10 | 0.0007 |
| 3 | Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC] | 1 | 0.0006 |
| 4 | Actinomycin [EPC] | 1 | 0.0005 |
| 5 | Carnitine Analog [EPC] | 1 | 0.0003 |
| 6 | Survival of Motor Neuron 2 Splicing Modifier [EPC] | 1 | 0.0002 |
| 7 | Topoisomerase Inhibitor [EPC] | 18 | 0.0002 |
| 8 | Antihypoglycemic Agent [EPC] | 1 | 0.0002 |
| 9 | Cephalosporin Antibacterial [EPC] | 2 | 0.0002 |